Functional Brands Issues Letter to ShareholdersMaking Everyone Healthy Again: A Milestone Moment and Strategic Vision for GrowthNovember 24, 2025 8:00 AM EST | Source: Functional Brands Inc.Lake Oswego, Oregon--(Newsfile Corp. - November 24, 2025) - Functional Brands Inc. (NASDAQ: MEHA), a leading innovator in wellness and performance products, issued the following letter from Eric Gripentrog, Chief Executive Officer.Dear Valued Shareholders,It is with great pride and enthusiasm that I write t ...

Core Insights - Protext Mobility, Inc. has announced a strategic Letter of Intent (LOI) with TruLeaf, which is expected to accelerate technology adoption and market expansion while introducing innovative financial applications leveraging CBD-based assets [1][4] Group 1: Technological Synergy & Bioavailability - TruLeaf's nanotechnology significantly enhances Protext's kettle technology, leading to increased bioavailability, making products more effective, faster, and more affordable for patients [2][3] - The partnership reduces production costs, thereby enhancing shareholder value and supporting the mission of global healing and patient wellbeing [3] Group 2: Regulatory & Competitive Advantage - The collaboration involves THC-free CBD FECO that complies with the Farm Bill, providing a clear market differentiation and competitive edge for Protext [3] Group 3: Financial Strengthening & Asset Potential - The resulting active pharmaceutical ingredient (API) is recognized as a real-world asset (RWA) under IFRS/GAAP, which strengthens the company's balance sheet and net profit without cash outflow [3] - These RWAs could support the creation of a stablecoin, enabling new financial opportunities such as staking or investment for the company and its shareholders [3] Group 4: Market Validation & Mission Impact - TruLeaf's support serves as a vote of confidence from an established partner, which is expected to accelerate Protext's growth, operational scaling, and market entry [3] - The partnership aligns with Protext's mission of "raising all boats," aiming to improve patient outcomes and create shareholder value [4]

Core Viewpoint - KRTL Holding Group Inc. has completed a PCAOB audit of its financial statements for the years ended December 31, 2024, and 2023, with no changes to previously reported unaudited amounts, and reported financial results for the three and nine months ended September 30, 2025, including contributions from its newly acquired subsidiary, Sigma [1][2][4]. Financial Performance - For the three months ended September 30, 2025, total revenues amounted to $1,815,781, with $1,752,656 generated from 28 days of operations of the Sigma subsidiary [2]. - Sigma generated approximately $19.7 million in revenue with a gross margin of 57% for the six months ended September 30, 2025, indicating an annualized revenue run rate of about $40 million [3]. Asset and Equity Position - As of September 30, 2025, KRTL Holding Group reported total assets of approximately $23.8 million and total shareholders' equity of $8.7 million [4]. Strategic Initiatives - The acquisition of Sigma is viewed as a scalable revenue base, with plans to expand distribution of pharmaceuticals and nutraceuticals internationally, including a potential entry into the U.S. market [3]. - The completion of the PCAOB audit positions the Company to pursue an uplisting to a higher-tier trading venue, which could enhance visibility and improve trading liquidity [4]. Company Overview - KRTL Holding Group operates through subsidiaries KRTL Biotech, Inc. and KRTL International Corp., leveraging strategic synergies across biotech, technology, and emerging markets to drive growth and deliver shareholder value [6].

Core Insights - Healthy Extracts Inc. reported its financial results for the third quarter and the first nine months of 2025, highlighting its position as a leader in plant-based nutraceutical innovations [1] Financial Performance - The company provided a comparison of its financial results to the same period in the previous year, indicating growth or changes in key metrics [1]

Financial Data and Key Metrics Changes - Total revenues increased 39% year-over-year to $9.1 million in Q3 2025, compared to $6.5 million in Q3 2024 [3][13] - Gross profit increased 50% to $5.6 million, representing 61% of total revenue, up from 57% in the same year-ago quarter [13][14] - Adjusted EBITDA loss narrowed to $0.4 million in Q3 2025 from a loss of $1.7 million in Q3 2024 [14] Business Line Data and Key Metrics Changes - Product revenue grew 30% to $8.4 million, while CDMO revenue surged 722% to $0.7 million [13][14] - Core capsules accounted for 88% of product revenues, with new products contributing approximately 30% of growth [4][5] Market Data and Key Metrics Changes - The US VINIA active user base exceeded 75,000 customers, contributing to revenue growth [3] - The launch of VINIA BloodFlow Hydration targets the $17 billion US electrolyte hydration market [9] Company Strategy and Development Direction - The company operates two business verticals: direct-to-consumer products and CDMO services, aiming to drive revenue from both branded products and B2B partnerships [4] - The recent capital raise of $19.9 million will fund the next growth phase, including tripling manufacturing capacity and expanding CDMO services [11][12] - The company aims to achieve adjusted EBITDA break-even by early 2026, with a focus on revenue growth and margin improvement [12][15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving positive adjusted EBITDA soon, emphasizing the importance of scaling operations and maintaining cost discipline [15][17] - The company is focused on executing the rollout of new products and expanding its Health Pros Affiliate Program to enhance customer acquisition [16][17] Other Important Information - The company secured a new CDMO partnership with SaffronTech to develop saffron-derived compounds, retaining a 25% ownership of the resulting product [5][6] - Gross profit margins improved due to increased manufacturing scale and improved yields [14] Q&A Session Summary Question: Expectations for the ramp-up of the new hydration product - Management indicated a staged launch with initial positive responses and expects a quarter-on-quarter ramp-up in sales, particularly after the broader launch on December 3 [19][22] Question: Update on CDMO opportunities and SaffronTech agreement - Management detailed the collaboration with SaffronTech, emphasizing a fast-tracked development process and the potential for a quick market entry [24][26] Question: Progress on existing CDMO contracts - Management provided updates on ongoing CDMO agreements, highlighting progress in the cosmetic fragrance space and the Tate & Lyle agreement [32][33] Question: Long-term outlook for CDMO business - Management projected that by 2027-2028, approximately 75% of revenue could come from the CDMO business, with margins significantly higher than the product business [47][49] Question: Early success with the HealthPros program - Management reported strong early engagement and conversion rates from HealthPros, with plans to onboard 300 professionals by year-end [41][43]

Core Insights - The company reported a nearly 20% year-over-year increase in total revenue, driven by higher bulk sales and strong online channel performance [3] - There was a significant improvement in gross margin due to increased production volumes, which lowered cost per unit and enhanced overall efficiency [3] - Price increases for Nutrex-branded products contributed to margin expansion, despite challenges from tariffs affecting contract extraction competitiveness [3] Financial Performance - Total revenue increased by nearly 20% year-over-year [3] - Improvement in gross margin was noted as production volumes increased [3] - Price increases earlier in the year for Nutrex-branded products aided in margin expansion [3] Operational Focus - The company emphasized operational excellence and disciplined cost control to build a stronger, more resilient business [3] - There is a commitment to long-term success despite external challenges such as tariffs [3]

Group 1 - Healthy Extracts Inc. has been invited to present at the annual fall Trickle Research Microcap Conference [1] - The conference will take place at Topgolf Centennial in Centennial, Colorado on November 13, 2025 [1] - A live stream of the conference will be available on the day of the event [1]

Core Insights - HBC reported total operating revenues of NOK 54.9 million in Q3 2025, down from NOK 67.9 million in the same period last year, attributed to lower commodity prices and a weaker U.S. dollar [1] - The company experienced an EBITDA of NOK -21.1 million, with operational EBITDA at NOK -12.9 million, excluding non-recurring costs [2] - Cash and cash equivalents decreased by NOK 2.6 million, ending at NOK 65.5 million, while total liquidity, including credit facilities, was NOK 67.0 million at quarter-end [3] Financial Performance - The Midsund plant processed 5,288 tonnes of raw material, marking the highest quarterly volume in HBC's history, with a gross margin improvement to 35% from 28% [8] - Human Nutrition B2B sales surged by 200% year-over-year, driven by products like OmeGo® and ProGo®, which also won the NutraIngredients-USA "Healthy Aging" Award [8] - Consumer & Pet Health (B2C) revenues grew by 30%, supported by new European listings and product extensions [8] Product Development and Innovation - HBC focuses on sustainability and optimal utilization of natural resources, converting salmon industry by-products into health-improving ingredients [4] - Key products include ProGo®, OmeGo®, and CalGo® / NT-II®, which have shown various health benefits, including improved iron metabolism and bone health [5][6] - HBC has established academic partnerships and secured patents for its discoveries, leading to the formation of HBC Immunology, which is developing therapeutics for prostate and ovarian cancer [6] Market Position and Strategy - HBC is listed on Oslo Børs under the ticker "HBC" and emphasizes scientific evidence in its product development [7] - The company aims to enhance its equity and liquidity position following a successful private placement in October 2025 [3]

Group 1: BETA Technologies - BETA Technologies went public on November 4, raising $1.015 billion by issuing 29.85 million shares at an initial price of $34 per share [3] - On its first trading day, BETA's stock opened at $34, reached a high of $38.33, and closed at $36, marking a 5.88% increase and a total market capitalization of $7.88 billion [1] - The company specializes in the development of electric vertical takeoff and landing (eVTOL) aircraft, including related electric propulsion systems and charging solutions [4] Group 2: Functional Brands - Functional Brands listed on NASDAQ through a direct listing, offering over 150 health supplement products, including probiotics, vitamins, and amino acids [4] - For the first half of 2025, Functional Brands reported revenue of $342,000, a slight decrease from $349,000 in the same period the previous year, with a net loss of $35,000 compared to a profit of $700 [4] Group 3: SPACs - Cantor Equity Partners V (CEPV) and Westin Acquisition (WSTNU) are both special purpose acquisition companies (SPACs) that entered NASDAQ, raising $220 million and $50 million, respectively [4] - CEPV, based in New York, aims to target acquisitions in financial services, digital assets, healthcare, real estate services, technology, and software sectors [5] - Westin Acquisition, headquartered in Singapore, plans to focus on companies in the Asia-Pacific region with significant growth potential [5]

Core Insights - The article discusses the potential of consumer defensive stocks, highlighting those with more than 50% upside potential in the current market environment [5][10]. Group 1: Market Analysis - Michel Lerner from UBS emphasizes the importance of focusing on quality defensive stocks rather than solely on value stocks, which may carry higher risks in uncertain economic conditions [2][3]. - Defensive stocks, particularly in Europe, have underperformed, resembling trends seen during the dot-com bubble, but are now presenting more attractive valuations [3][4]. - Earnings pressures for some defensive stocks are beginning to ease, providing a hedge in a risk-on market environment [4]. Group 2: Stock Recommendations - JBS N.V. (NYSE:JBS) has an analyst upside of 51.40% with a price target set at $20 by Bank of America Securities, despite recent adjustments to EBITDA and EPS forecasts due to challenges in the US chicken market [10][11][12]. - BioHarvest Sciences Inc. (NASDAQ:BHST) shows an analyst upside of 51.52% and has entered a strategic agreement with Saffron Tech to develop saffron-derived compounds, aiming for large-scale production and direct-to-consumer marketing [13][15][16].